The aim of our study was to determine the prevalence of chronic pulmonary aspergillosis in pulmonary tuberculosis patients and the antifungal resistance of Aspergillus spp. isolates in Uzbekistan. Chronic pulmonary aspergillosis was detected in 11.4% and 20.0% of smear-positive and smear-negative pulmonary tuberculosis patients, respectively.
DenningDWCadranelJBeigelman-AubryC, et al. European Society for clinical microbiology and infectious diseases and European respiratory society. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J2016; 47: 45–68.
2.
SmithNLDenningDW. Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J2011; 37: 65–872.
3.
BrownGDDenningDWGowNA, et al. Hidden killers: human fungal infections. Sci Transl Med2012; 4: 165rv13.
4.
PageIDByanyimaRHosmaneS, et al. Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation. Eur Respir J2019; 53:1801184.
5.
BongominFGagoSOladeleRO, et al. Global and multi-national prevalence of fungal diseases-estimate precision. J Fungi (Basel) 2017; 3: 57.
6.
DenningDWPleuvryAColeDC. Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull World Health Organ2011; 89: 864–872.
7.
JewkesJKayPHPanethM, et al. Pulmonary aspergilloma: analysis of cavitating invasive pulmonary aspergillosis in immunocompromised patients. Ann Thorac Surg1983; 53: 621.
8.
CamusetJNunesHDombretMC, et al. Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest2007; 131: 1435–1441.
9.
SafaevKParpievaNLiverkoI, et al. Trends, characteristics and treatment outcomes of patients with drug-resistant Tuberculosis in Uzbekistan: 2013–2018. Int J Environ Res Public Health2021; 18: 4663.
10.
van KampenSCWannerAEdwardsM, et al. International research and guidelines on post-tuberculosis chronic lung disorders: a systematic scoping review. BMJ Glob Heal2018; 3: e000745
11.
KhanRMalikNIRazaqueA. Imaging of pulmonary post-tuberculosis sequelae. Pakistan J Med Sci2020; 36: S75–S82.
12.
Thoracic British and Association Tuberculosis. Aspergilloma and residual tuberculosis cavities-the results of a resurvey. Tubercle1970; 51(3): 227–245.
13.
BongominF. Post-tuberculosis chronic pulmonary aspergillosis: an emerging public health concern. PLoS Pathog2020; 16: e1008742.
14.
OladeleROIrurheNKFodenP, et al. Chronic pulmonary aspergillosis as a cause of smear-negative TB and/or TB treatment failure in Nigerians. Int J Tuberc Lung Dis2017; 21: 1056–1061
15.
KwizeraRKatendeATeuA, et al. Algorithm-aided diagnosis of chronic pulmonary aspergillosis in low- and middle-income countries by use of a lateral flow device. Eur J Clin Microbiol Infect Dis2020; 39: 1–3.
16.
KoyamaKOhshimaNSuzukiJ, et al. Recurrence of chronic pulmonary aspergillosis after discontinuation of maintenance treatment by antifungal triazoles. J Infect Chemother2014; 20: 375–379.
17.
World Health Organization. Early detection of tuberculosis: an overview of approaches, guidelines and tools. Geneva: World Health Organization, 2011, Available from: https://apps.who.int/iris/handle/10665/70824
KeflieTSAmeniG. Microscopic examination and smear negative pulmonary tuberculosis in Ethiopia. Pan Afr Med J2014; 19: 162.
20.
SalzerHJHeyckendorfJKalsdorfB, et al. Characterization of patients with chronic pulmonary aspergillosis according to the new ESCMID/ERS/ECMM and IDSA guidelines. Mycoses2017; 60: 136–142.
21.
KanjAAbdallahNSoubaniAO. The spectrum of pulmonary aspergillosis. Respir Med2018; 141: 121–131.
World Health Organization. (Global Tuberculosis Programme) Global Tuberculosis Report 2020; World Health Organization: Geneva, Switzerland, 2020. ISBN 9789240013131
24.
YuldashevSParpievaNAlimovS, et al. Scaling up molecular diagnostic tests for drug-resistant Tuberculosis in Uzbekistan from 2012–2019: are we on the right track?Int J Environ Res Public Health2021; 18: 4685.
TilavberdievSADenningDWKlimkoNN. Serious fungal diseases in the republic of Uzbekistan. Eur J Clin Microbiol Infect Dis2017; 36 : 925–929.
27.
TurdumambetovaGKOsmanovADenningDW. The burden of serious fungal infections in Kyrgyzstan. J Fungi (Basel) 2019; 5: 66.
28.
KemaykinVMTabinbaevNBKhudaibergenovaMS, et al. An estimate of severe and chronic fungal diseases in the republic of Kazakhstan. J Fungi (Basel) 2018; 4: 34.
29.
BobokhojaevOIOsmanovAAlievSP, et al. The burden of serious fungal infections in Tajikistan. J Fungi (Basel) 2019; 5: 68.
30.
JabeenKFarooqiJMirzaS, et al. Serious fungal infections in Pakistan. Eur J Clin Microbiol Infect Dis2017; 36: 949–956.
31.
SharpeARLagrouKMeisJF, et al. On behalf of the ISHAM/ECMM Aspergillus resistance surveillance working group triazole resistance surveillance in Aspergillus fumigatus. Med Mycol2018; 56: S83–S92.
32.
HerbrechtRDenningDWPattersonTF, et al. Invasive fungal infections group of the European organization for research and treatment of cancer and the global Aspergillus study group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med2002; 347: 408–415.
33.
PoppAIWhiteMHQuadriT, et al. Amphotericin B with and without itraconazole for invasive aspergillosis: a three-year retrospective study. Int J Infect Dis1999; 3: 157–160.
34.
BowdenRChandrasekarPWhiteMH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis2002; 35: 359–366.
35.
WhiteMHAnaissieEJKusneS, et al. Amphotericin B colloidal dispersion vs. Amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis1997; 24: 635–642.
